U.S. FDA Counts 62 Deaths That Could Be Tied To Chinese Heparin
This article was originally published in PharmAsia News
The U.S. FDA says it has received 62 reports of deaths that could be tied to Chinese-produced heparin, more than triple the numbers announced previously. The 62 died within the past 15 months of allergic reactions or low blood pressure, symptoms involved with contaminated heparin. The FDA cautions the heparin may not be the cause of death in all cases. Baxter International recalled most of the product in February, but the drug was produced from basic supplies also shipped to other makers of the drug, such as APP Pharmaceuticals, which said its users were not among the 62 listed by the FDA. (Click here for more
You may also be interested in...
BEIJING - U.S. FDA last week issued a sharply higher estimate on the number of deaths that have occurred in patients who suffered allergic reactions to the blood thinner heparin
Tandem Diabetes Care and Medtronic have signed a patent cross-license agreement that paves the way for joint development of future diabetes products and services while avoiding potential legal disagreements.
Thanks in part to budget authority bump, US FDA’s generic user fee revenue spending dropped in FY 2019, and hiring problems lead to an FTE decrease. The useable GDUFA carryover balance also increased in conjunction with the user fee revenue spending reduction, from $158.7m available at the end of FY 2018 to $199.2m at the end of FY 2019.